The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome
Open accessAbstract
Identifying patients who are potential placebo responders has major implications for clinical practice and trial design. Catechol-O-methyltransferase (COMT), an important enzyme in dopamine catabolism plays a key role in processes associated with the placebo effect such as reward, pain, memory and learning. We hypothesized that the COMT functional val158met polymorphism, was a predictor of placebo effects and tested our hypothesis in a subset of 104 patients from a previously reported randomized controlled trial in irritable bowel syndrome (IBS). The three treatment arms from this study were: no-treatment ("waitlist"), placebo treatment alone ("limited") and, placebo treatment "augmented" with a supportive patient-health care provider interaction. The primary outcome measure was change from baseline in IBS-Symptom Severity Scale (IBS-SSS) after three weeks of treatment. In a regression model, the number of methionine alleles in COMT val158met was linearly related to placebo response as measured by changes in IBS-SSS (p = .035). The strongest placebo response occurred in met/met homozygotes treated in the augmented placebo arm. A smaller met/met associated effect was observed with limited placebo treatment and there was no effect in the waitlist control. These data support our hypothesis that the COMT val158met polymorphism is a potential biomarker of placebo response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788 · cited 1×
“COMT val158met, is a G to A transition leading to amino-acid substitution at codon 158 in the transmembrane form of the enzyme [8].”
BackgroundFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593 · cited 1×
“The inverted U-shaped dopamine response curve, reported in many COMT functional studies suggests a narrow range for optimum dopamine cortical function [48,49].”
BackgroundAGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Diatchenko, L., Slade, G. D., Nackley, A. G., Bhalang, K., Sigurdsson, A., Belfer, I., Goldman, D., Xu, K., Shabalina, S. A., Shagin, D., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi013 · Cited by 1,280 · cited 3×
“This functional polymorphism has been correlated with variations in memory function [10,11], cognition [12], attentional processing [13], affect [14], confirmation bias [15], pain processing and sensitivity [16,17,18,19].”
BackgroundComponents of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., Kirsch, I., Schyner, R. N., Nam, B. H., Nguyen, L. T., et al. (2008) · BMJ · doi:10.1136/bmj.39524.439618.25 · Cited by 1,196 · cited 8×
“002), in which patients in the augmented placebo arm showed most improvement and those in the waitlist arm showed the least [30].”
BackgroundResultInfluentialSelf-citationNackley, A. G., Shabalina, S. A., Tchivileva, I. E., Satterfield, K., Korchynskyi, O., Makarov, S. S., Maixner, W., & Diatchenko, L. (2006) · Science · doi:10.1126/science.1131262 · Cited by 848
Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors
Zubieta, J.-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., Nichols, T. E., & Stohler, C. S. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0439-05.2005 · Cited by 779 · cited 1×
“Studies investigating brain activity associated with placebo response in pain, Parkinson’s disease and depression, point to dopamine as a possible integrator of the placebo response [2,3,4,5].”
BackgroundIndividual differences in reward responding explain placebo-induced expectations and effects
Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.028 · Cited by 466
Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype
Meyer-Lindenberg, A., Kohn, P. D., Kolachana, B., Kippenhan, S., McInerney-Leo, A., Nussbaum, R., Weinberger, D. R., & Berman, K. F. (2005) · Nature Neuroscience · doi:10.1038/nn1438 · Cited by 428
The placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285 · cited 1×
“IBS is a condition known to have a high placebo response rate and meta-analyses report an average placebo induced global improvement of approximately 40% [27,28,29].”
BackgroundSelf-citationTolcapone improves cognition and cortical information processing in normal human subjects
Apud, J. A., Mattay, V., Chen, J., Kolachana, B. S., Callicott, J. H., Rasetti, R., Alce, G., Iudicello, J. E., Akbar, N., Egan, M. F., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301227 · Cited by 242 · cited 2×
“Four other placebo-controlled studies designed to examine the effects of tolcapone, a COMT inhibitor, looked at the association between COMT val158met genotype, cognition and information processing [42,43,44,45].”
BackgroundFurmark, T., Appel, L., Henningsson, S., Åhs, F., Faria, V., Linnman, C., Pissiota, A., Frans, Ö., Bani, M., Bettica, P., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2534-08.2008 · Cited by 210
Patient and practitioner influences on the placebo effect in irritable bowel syndrome.
Kelley, J. M., Lembo, A. J., Ablon, J. S., Villanueva, J. J., Conboy, L. A., Levy, R., Marci, C. D., Kerr, C. E., Kirsch, I., Jacobson, E. E., et al. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181acee12 · Cited by 208
Self-citationDorn, S. D., Kaptchuk, T. J., Park, J. B., Nguyen, L. T., Canenguez, K., Nam, B. H., Woods, K. B., Conboy, L. A., Stason, W. B., & Lembo, A. J. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00937.x · Cited by 119
Self-citation
Cited by
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Placebo and the New Physiology of the Doctor-Patient Relationship
Benedetti, F. (2013) · Physiological Reviews · doi:10.1152/physrev.00043.2012 · Cited by 492
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
Placebo Effects: From the Neurobiological Paradigm to Translational Implications
Benedetti, F. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.023 · Cited by 317
Petrie, K. J., & Rief, W. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102907 · Cited by 309
Metadata
- Authors
- Hall, K. T., Lembo, A. J., Kirsch, I., Ziogas, D. C., Douaiher, J., Jensen, K. B., Conboy, L. A., Kelley, J. M., Kokkotou, E., & Kaptchuk, T. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-23
- Volume
- 7
- Issue
- 10
- Pages
- e48135
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2151270602
- Cited by
- 205
- References
- 15
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.